Mercury Lab Peer Comparison

BSE: 538964

₹773.65

₹-7.35 (-0.94%)

As on 28-Aug-2026IST

Market cap

₹93 Cr

Revenue (TTM)

₹74 Cr

P/E Ratio

22.3

P/B Ratio

1.6

Div. Yield

0.5 %

Edit

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	93	21,543	19,151	18,073	17,547
Revenue (₹ Cr)	74	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	4.16	735.15	678.07	666.92	169.62
Net Margin (%)	5.51	26.88	28.10	20.60	6.90
RoE (%)	7.80	19.16	19.73	18.75	20.76
Price to Earnings	22.30	29.30	28.78	28.07	103.45
Price-To-Book	1.59	4.89	5.09	4.47	19.41

Income Statement (₹ Cr)

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	73.76	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	75.59	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	65.88	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	7.88	941.63	796.58	1,139.61	229.86
Depreciation	3.31	57.58	78.10	281.06	17.24
EBIT	4.58	884.05	718.48	858.55	212.62
Interest	0.52	7.69	0.88	190.64	5.72
Other Income	1.83	165.62	125.96	7.45	26.48
Exceptional Items	-0.40	-49.16	0.00	-17.24	-5.13
Profit before Tax	5.48	992.82	843.56	658.12	228.25
Provision for Tax	1.32	257.67	165.49	-8.80	58.63
Profit after Tax	4.16	735.15	678.07	666.92	169.62

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	58.08	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	9.32	91.50	28.74	1,392.75	134.50
Current Liabilities	11.69	627.48	385.94	2,077.10	981.81
Total Liabilities	74.24	4,911.11	3,207.85	6,862.28	1,879.19

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	32.78	770.28	1,291.22	5,617.77	42.47
Current Assets	44.95	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	74.24	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	4.09	2.50	0.55	2,421.66	0.00
Net Current Assets	33.26	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	3.26	363.79	0.64	64.29	98.41

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	4.00	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	-9.04	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	-0.99	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	-6.03	383.07	59.32	103.72	30.57

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	9.14	26.21	26.22	13.59	21.29
ROE (%)	7.80	19.16	19.73	18.75	20.76
ROA (%)	5.43	14.95	18.69	9.26	9.67
EBIT Margin (%)	6.20	34.40	31.41	26.58	8.74
Net Margin (%)	5.51	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	-3.65	10.69	15.01	9.59	31.10
EBIT Growth (%)	-3.54	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	10.42	-9.09	19.61	62.68	-7.49
EPS Growth (%)	17.74	14.40	17.73	67.41	-18.33
Book Value Growth (%)	5.37	17.30	23.77	10.19	7.70

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	20.91	27.87	28.74	27.66	102.37
Price / Book Value	1.59	4.88	5.08	4.51	19.65
Dividend Yield (%)	0.45	1.60	0.16	0.55	0.51
EV/EBITDA	12.02	19.53	22.88	17.94	75.34
Market Cap (₹ Cr)	98.28	18,318.10	15,219.80	19,292.77	21,515.93

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.12	0.00	0.00	0.24	0.00
Short term debt to equity ratio	0.01	0.00	0.00	0.14	--
Current Ratio	3.85	6.06	6.70	0.74	1.77
Quick Ratio	3.24	5.31	5.59	0.53	0.73
Interest Coverage	11.46	130.11	959.59	4.45	40.90

	Mercury Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	35.04	7.07	36.10	21.07	8.79
Asset Turnover	0.96	0.52	0.63	0.45	1.39
Receivable days	115.65	29.10	110.70	54.07	35.81
Inventory Days	32.60	69.53	65.86	32.16	82.25
Payable days	152.93	76.77	105.88	140.91	124.39
Cash Conversion Cycle	-4.69	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.